New registry to monitor YORVIPATH's effects on pregnant women and babies
NCT ID NCT07345494
First seen Jan 19, 2026 · Last updated May 10, 2026 · Updated 12 times
Summary
This study is a pregnancy registry that collects information from women aged 15 to 50 who took YORVIPATH for hypoparathyroidism around the time of conception or during pregnancy. Researchers will track pregnancy complications, birth outcomes, and infant health for at least one year after birth. The goal is to better understand any risks to mothers, fetuses, and babies from this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGMorgantown, West Virginia, 26508, United States
Conditions
Explore the condition pages connected to this study.